Definate agreement with celly nutrition The Definitive Agreement with Celly Nutrition also includes royalty payments of 7% of sales from unbuzzd ™ until payments to FSD Pharma total $250 million.
Once $250 million is reached, the royalty drops to 3% in perpetuity. With only 42 (42,164,573 May 17, 2024)million shares outstanding in HUGE, if qualified sales are achieved, the $250 million in future royalties are worth over $5. 00 per share in revenue, with additional royalties flowing after that. Additionally, FSD Pharma retains a tax loss carryforward of approximately CAD $130 million, and could be utilized in the future to offset tax payable obligations against future profits.